Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Prothena Corporation PLC    PRTA   IE00B91XRN20

PROTHENA CORPORATION PLC (PRTA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2018 06/15/2018 06/18/2018 06/19/2018 06/20/2018 Date
14.7(c) 14.85(c) 14.56(c) 14.98(c) 15.4 Last
416 350 4 532 953 440 496 588 804 625 984 Volume
+2.58% +1.02% -1.95% +2.88% +2.80% Change
More quotes
Financials (USD)
Sales 2018 5,97 M
EBIT 2018 -154 M
Net income 2018 -152 M
Finance 2018 353 M
Yield 2018 -
Sales 2019 33,4 M
EBIT 2019 -102 M
Net income 2019 -106 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 38,0x
Capi. / Sales2019 17,4x
Capitalization 580 M
More Financials
Company
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories.Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease.The company... 
More about the company
Surperformance© ratings of Prothena Corporation PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTHENA CORPORATION PLC
03:36pSCOTT+SCOTT ATTORNEYS AT LAW LLP : Reminds Investors of Securities Class Action ..
PR
06/19PROTHENA : Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkin..
GL
06/19PROTHENA CORPORATION PLC : Pomerantz Law Firm Investigates Claims On Behalf of I..
AC
06/16PROTHENA CORPORATION PLC : Pomerantz Law Firm Investigates Claims On Behalf of I..
AC
06/14PROTHENA CORPORATION PLC : PRTA NEWS: Pawar Reminds of Important July 16, 2018 L..
AC
06/14PROTHENA CORPORATION PLC : Pomerantz Law Firm Investigates Claims On Behalf of ..
AC
06/13THE KLEIN LAW FIRM : Reminds Investors of a Class Action Commenced on Behalf of ..
BU
06/12PROTHENA CORPORATION PLC : SHAREHOLDER ACTION ALERT: The Schall Law Firm Announc..
AC
06/12PRTA The Law Offices of Vincent Wong Reminds Investors of Commencement of a C..
BU
06/12PROTHENA CORPORATION PLC : IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announ..
AC
More news
Sector news : Bio Therapeutic Drugs
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04:13pPRTA INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class .. 
04:10pScott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action.. 
02:45pWant the latest upgrades & downgrades for $CMGE $PRTA $APAM $RDFN $BSF? C.. 
04:12aProthena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parki.. 
12:09a$PRTA: Prothena announces Phase 1b clinical results of PRX002/RG7935 for Park..
1
More tweets
Qtime:56
News from SeekingAlpha
06/19Prothena up 1% after publishing positive Parkinson's treatment data 
06/08Eidos Therapeutics Readies $100 Million U.S. IPO 
05/29Prothena Still Remains A Great Short Opportunity After Workforce Reduction 
05/25Eidos Therapeutics files for initial public offering 
05/21Premarket analyst action - healthcare 
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation PLC Technical Analysis Chart | PRTA | IE00B91XRN20 | 4-Traders
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 14,1 $
Spread / Average Target -5,7%
EPS Revisions
Managers
NameTitle
Gene G. Kinney President, Chief Executive Officer & Director
Lars G. Ekman Chairman
Tran B. Nguyen Chief Financial Officer
Wagner Zago Chief Scientific Officer
Richard T. Collier Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTHENA CORPORATION PLC-61.16%580
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
REGENERON PHARMACEUTICALS-16.13%33 439
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076